We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Breakthrough Enables Manipulation of the Chlamydia Genome

By LabMedica International staff writers
Posted on 14 Nov 2011
A team of microbiologists and molecular biologists believes that they have achieved a breakthrough in the study of Chlamydia genetics that could pave the way for the development of new treatments and possibly of a vaccine for this sexually transmitted disease.

Chlamydia trachomatis is a major human pathogen for which investigators have failed in attempts to manipulate genetically its DNA. More...
It is an obligate intracellular bacterium, which has a complex developmental cycle that takes place in a specialized host cell cytoplasmic vacuole known as an inclusion. The extracellular infectious elementary body (EB) is an infectious, electron-dense structure that, following host cell infection, differentiates into a noninfectious replicative form known as a reticulate body (RB).

In a paper published in the September 22, 2011, online edition of the journal PLoS Pathogens investigators at the University of Southampton (United Kingdom) and Ben Gurion University of the Negev (Be’er Sheva, Israel) reported that they had achieved a significant breakthrough in accessing the chlamydial genome.

This feat was accomplished by isolating penicillin resistant Chlamydia that were then treated with calcium chloride (CaCl2). Penicillin prevented the maturation of RBs into EBs. Instead, the RBs failed to divide although DNA replication continued. The investigators exploited these observations to develop a transformation protocol based on expression of beta-lactamase. They constructed a vector that carried both the chlamydial endogenous plasmid and a replication plasmid of E. coli origin so that the vector could shuttle between these two bacterial recipients. Proof of the method was obtained by insertion of the gene for a fluorescent protein into C. trachomatis, which identified chlamydial-infected cells by making them glow green.

"This is a very significant advance in the study of Chlamydia and we are proud to be the first people to achieve this,” said senior author Dr. Ian Clarke, professor of molecular microbiology at the University of Southampton. “Previously people have been unable to study chlamydial genetics, and this has created a barrier to the comprehensive study of this disease. We, together with our colleagues in Israel, discovered that by treating the Chlamydia with calcium ions we were able to introduce a piece of foreign DNA. This will open up the field of Chlamydia research and will enable a better understanding of chlamydial genetics. It could lead to the development of new approaches to chlamydial vaccines and therapeutic interventions.”

Related Links:
University of Southampton
Ben Gurion University of the Negev



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
New
Urine Microscopy Analyzer
DxU 850m Iris
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.